References
- AbbVie and Calico Announce Extension of Groundbreaking Collaboration. www.calicolabs.com/news/2018/06/26/.
- Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn. www. novartis.com/news/media-releases/novartis-announces-intention-seek-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bn.
- Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson's Disease. www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-and-axovant-sciences-enter-8425-million-exclusive.
- Merck and Alibaba Health Announce Collaboration to Develop Patient-Centric Digital Services in China. www.merckgroup.com/content/dam/web/corporate/non-images/press-releases/2018/jun/en/Merck-Alibaba-Health-Partnership-EN.pdf.
- Mylan Provides Statement on Generic Advair Diskus®. http://newsroom.mylan.com/press-releases?item=123580.
- GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution–the First Plant-derived Cannabinoid Prescription Medicine. www.gwpharm.com/about-us/news/gw-pharmaceuticals-plc-and-its-us-subsidiary-greenwich-biosciences-announce-fda.
- PHASE II CLINICAL STUDY OF ELENBECESTAT DEMONSTRATES SAFETY AND TOLERABILITY IN MCI AND MILD TO MODERATE ALZHEIMER's DISEASE AT 18-MONTHS. www.eisai.com/news/2018/news201844.html.
- Update on Phase III clinical trials of lanabecestat for Alzheimer's disease. www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html.
- Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache. www.tevapharm.com/news/teva_provides_update_on_clinical_trial_of_fremanezumab_for_use_in_chronic_cluster_headache_06_18.aspx.
- Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018. https://news.bms.com/press-release/preliminary-data-nktr-214-combination-opdivo-nivolumab-patients-stage-iv-metastatic-me.
- Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study. http://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Plus-Chemotherapy-Significantly-Improved-Overall-Survival-in-First-Line-Treatment-of-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer-in-Phase-3-KEYNOTE-407-Study/default.aspx.
- Eisai and Merck & Co., Inc., Kenilworth, NJ, USA, announce data at 2018 ASCO Annual Meeting from investigationalstudies of Lenvima® and Keytruda® combination therapy in four different tumortypes. www.eisai.com/news/2018/news201843.html.
- Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting. https://ir. loxooncology.com/press-releases/loxo-oncology-announces-positive-interim-clinical-data-from-loxo-292-dose-escalation-trial-in-ret-altered-cancers-presented-at-the-american-society-of-clinical-oncology-annual-meeting.
- Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting. https://ir.celgene.com/press-releases/press-release-details/2018/Updated-Results-of-Ongoing-Multicenter-Phase-I-Study-of-bb2121-anti-BCMA-CAR-T-Cell-Therapy-Continue-to-Demonstrate-Deep-and-Durable-Responses-in-Patients-with-Late-Stage-RelapsedRefractory-Multiple-Myeloma-at-ASCO-Annual-Meeting/default.aspx.
- GRAIL Announces Data From Early Research Analyzing its High-Intensity Sequencing Approach. https://globenewswire.com/news-release/2017/06/03/1007917/0/en/GRAIL-Announces-Data-From-Early-Research-Analyzing-its-High-Intensity-Sequencing-Approach.html.